



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville MD 20857

July 1, 2013

**FILE COPY**

Christine Miller, Pharm.D  
Associate Director  
Lachman Consultant Services, Inc.  
1600 Stewart Avenue  
Westbury, NY 11590

Dear Dr. Miller:

Your petition to the Food and Drug Administration requesting to declare that the drug products, Griseofulvin Tablets, 187.5 mg, and Griseofulvin Tablets, 375mg, are suitable for submission as an ANDA, was received by this office on 07/01/2013. It was assigned docket number FDA-2013-P-0799/CP1, and it was filed on 07/01/2013. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

A handwritten signature in cursive script, reading "Gloria Ortega", is positioned above the printed name.

Gloria Ortega  
Administrative Proceedings Officer  
Division of Dockets Management  
FDA/Office of the Executive Secretariat (OES)